GW and Otsuka to take Sativex to Phase III for cancer pain
This article was originally published in Scrip
GW Pharmaceuticals and its US licensing partner Otsuka Pharmaceuticals are to take their cannabis extract CB1 agonist Sativex Oromucosal Spray (nabiximols) into Phase III development for the treatment of pain in patients with advanced cancer after it yielded mixed results in a Phase IIb study.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.